A 32-year-old male presents to the de-addiction clinic with a 6-year history of heroin use. He reports using 2–3 grams daily via inhalation and injection. On examination, he is alert and oriented, with dilated pupils and mild tremor. His vital signs are: HR 98 bpm, BP 128/82 mmHg, RR 18/min, temperature 37.2°C. He reports last use 18 hours ago. He is motivated for treatment and has stable housing and employment. Which is the most appropriate maintenance therapy for this patient?

Explanation

## Opioid Maintenance Therapy Selection **Key Point:** Buprenorphine is the first-line maintenance agent for opioid use disorder in most settings, particularly in India, due to its superior safety profile, lower abuse potential, and reduced overdose risk compared to methadone. ### Why Buprenorphine Is Preferred Buprenorphine is a partial μ-opioid agonist with the following advantages: 1. **Ceiling effect on respiratory depression** — overdose risk is significantly lower than with full agonists 2. **Lower abuse potential** — sublingual formulation has poor bioavailability when injected 3. **Flexible dosing** — can be dosed every 48–72 hours due to long half-life (~37 hours) 4. **Easier withdrawal** — tapering produces milder withdrawal symptoms than methadone 5. **Regulatory accessibility** — widely available in India; methadone programs require stricter licensing ### Dosing and Induction For this patient with moderate daily use (2–3 g heroin), induction typically begins at **4–8 mg daily** and titrates upward based on withdrawal symptoms and cravings. The standard maintenance dose ranges from 8–24 mg daily. **Clinical Pearl:** Buprenorphine should be initiated **only after early signs of withdrawal** (pupil dilation, tremor, anxiety) appear — premature dosing risks precipitated withdrawal due to its high receptor binding affinity displacing other opioids. ### Comparison with Alternatives | Feature | Buprenorphine | Methadone | Naltrexone | Clonidine | | --- | --- | --- | --- | --- | | **Agonist type** | Partial μ agonist | Full μ agonist | Pure antagonist | α-2 agonist (non-opioid) | | **Overdose risk** | Low (ceiling effect) | High | None (antagonist) | None | | **Abuse potential** | Low | High | None | Low | | **Withdrawal severity** | Mild–moderate | Severe | Severe | Mild | | **Half-life** | 37 hours | 24–36 hours | 10 hours | 12–16 hours | | **Dosing frequency** | Daily or every 48–72 h | Daily | Daily | Twice daily | | **Regulatory status (India)** | Widely available | Restricted licensing | Available | Available | **High-Yield:** In India, buprenorphine is the **de facto standard** for opioid maintenance because methadone programs require specialized centers and strict DEA-like oversight, whereas buprenorphine can be prescribed in primary care and de-addiction clinics. ### Why Other Options Are Suboptimal - **Methadone:** Full agonist with high overdose risk, severe withdrawal, and stricter regulatory requirements. Reserved for patients who fail buprenorphine or have specific clinical indications (e.g., severe pain comorbidity). - **Naltrexone:** Pure antagonist; high relapse rates due to lack of opioid effect. Useful only in highly motivated patients with strong psychosocial support and primarily for relapse prevention post-detoxification. - **Clonidine:** Non-opioid α-2 agonist; addresses withdrawal symptoms (tremor, anxiety, hypertension) but does NOT reduce cravings or provide opioid replacement. Used only as adjunctive therapy during detoxification, not maintenance. **Mnemonic:** **BUPE** = **B**est for **U**se in **P**rimary care, **E**asy to prescribe (buprenorphine's advantages in the Indian context).